急性髓系白血病化疗合并感染的危险因素及风险评估

胡霞; 陈乃耀

doi:10.13201/j.issn.1004-2806.2021.03.015

急性髓系白血病化疗合并感染的危险因素及风险评估

胡霞¹,
陈乃耀^2, ,

- 1. 华北理工大学临床学院(河北唐山, 063000);
- 2. 华北理工大学附属医院血液内科

详细信息

通讯作者: 陈乃耀,E-mail:nychenncmc@163.com

中图分类号: R733.71

收稿日期: 2020-12-01

Risk factors and risk assessment of chemotherapy-associated infection in acute myeloid leukemia

HU Xia¹,
CHEN Naiyao^2, ,

More Information

Corresponding author: CHEN Naiyao, E-mail: nychenncmc@163.com

Received Date: 01 December 2020

摘要

- 急性髓系白血病 /
- 感染 /
- 危险因素 /
- 风险评估
Abstract: Chemotherapy complicated with infection in acute myeloid leukemia(AML) has been a hot topic in hematology research. Chemotherapy is the main treatment for AML, and the adverse events caused by chemotherapy are not to be underestimated. Among them, infection is the most common adverse events. There are many risk factors for infection. It is generally believed that AML chemotherapy-complicated infection is associated with primary disease and chemotherapy-related immunodeficiency, patient-specific risk factors, and treatment-related skin and mucous membrane injury. In AML patients, infection not only affects the treatment effect, but also leads to an increase of mortality. Therefore, the risk assessment of infection after chemotherapy is very important, and MASCC score combined with individual risk factors is of certain value in predicting the risk of infection. Herein, we reviewed the latest knowledge of risk factors and risk assessment for infection following AML chemotherapy, so as to help the prevention and treatment of AML chemotherapy-associated infection.
- acute myeloid leukemia /
- infection /
- risk factors /
- risk assessment

HTML全文

参考文献(38)

[1]	魏辉,杨秒,李寿芸.老年急性髓系白血病的整体治疗策略[J].临床血液学杂志,2020,33(5):297-301.
[2]	Döhner H,Weisdorf DJ,Bloomfield CD.Acute myeloid leukemia[J].N Engl J Med,2015,373(12):1136-1152.
[3]	Döhner H,Estey E,Grimwade D,et al.Diagnosis and management of AML in adults:2017 ELN recommendations from an international expert panel[J].Blood,2017,129(4):424-447.
[4]	Sekeres MA,Guyatt G,Abel G,et al.American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults[J].Blood Adv,2020,4(15):3528-3549.
[5]	Kato H,Fujita H,Akiyama N,et al.Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols[J].Support Care Cancer,2018,26(12):4187-4198.
[6]	Goswami M,Prince G,Biancotto A,et al.Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy[J].J Transl Med,2017,15(1):155.
[7]	Othus M,Kantarjian H,Petersdorf S,et al.Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens:a report from SWOG and MD Anderson[J].Leukemia,2014,28(2):289-292.
[8]	Halpern AB,Culakova E,Walter RB,et al.Association of risk factors,mortality,and care costs of adults with acute myeloid leukemia with admission to the intensive care unit[J].JAMA Oncol,2017,3(3):374-381.
[9]	冯四洲,陈欣.血液病患者多药耐药革兰氏阴性菌感染的经验性治疗策略[J].临床血液学杂志,2019,32(3):170-173.
[10]	Hansen BA,Wendelbo ø,Bruserud ø,et al.Febrile neutropenia in acute etiology,pathophysiology and treatment[J].Mediterr J Hematol Infect Dis,2020,12(1):e2020009.
[11]	Teng TS,Ji Al,Ji XY,et al.Neutrophils and immunity:from bactericidal action to being conquered[J].J Immunol Res,2017,2017:9671604.
[12]	Freifeld AG,Bow EJ,Sepkowitz KA,et al.Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer:2010 update by the Infectious Diseases Society of America[J].Clin Infect Dis,2011,52(4):e56-e93.
[13]	Gao C,Wang J,Li Y,et al.Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia:A systematic review and meta-analysis[J].Medicine(Baltimore),2018,97(34):e11860.
[14]	Jalbut MM,Brunner AM,Amrein PC,et al.Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia[J].Leuk Lymphoma,2018,59(4):988-991.
[15]	Tang L,Wu J,Li CG,et al.Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia[J].Clin Cancer Res,2020,26(7):1763-1772.
[16]	Goswami M,Prince G,Biancotto A,et al.Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy[J].J Transl Med,2017,15(1):155.
[17]	Pehlivan M,Sahin HH,Ozdilli K,et al.Gene polymorphisms and febrile neutropenia in acute leukemia--no association with IL-4,CCR-5,IL-1RA,but the MBL-2,ACE,and TLR-4 are associated with the disease in Turkish patients:a preliminary study[J].Genet Test Mol Biomarkers,2014,18(7):474-481.
[18]	Klepin HD,Estey E,Kadia T.More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia:New Perspectives on an Old Debate[J].Am Soc Clin Oncol Educ Book,2019,39:421-432.
[19]	Almeida AM,Ramos F.Acute myeloid leukemia in the older adults[J].Leuk Res Rep,2016,6:1-7.
[20]	Matias Cdo N,Lima V,Teixeira HM,et al.Hyperglycemia increases the complicated infection and mortality rates during induction therapy in adult acute leukemia patients[J].Rev Bras Hematol Hemoter,2013,35(1):39-43.
[21]	Tawfik B,Pardee TS,Isom S.Comorbidity,age,and mortality among adults treated intensively for acute myeloid leukemia(AML)[J].J Geriatr Oncol,2016,7(1):24-31.
[22]	Müller L,Benedetto SD,Pawelec G.The Immune System and Its Dysregulation with Aging[J].Subcell Biochem,2019,91:21-43.
[23]	Choi EH.Aging of the skin barrier[J].Clin Dermatol,2019,37(4):336-345.
[24]	成晓晴,吴利东.中心静脉导管与深静脉血栓形成的关系研究[J].临床急诊杂志,2019,20(12):989-992.
[25]	Sousa B,Furlanetto J,Hutka M,et al.Central venous access in oncology:ESMO clinical practice guidelines[J].Ann Oncol,2015,26 Suppl 5:v152-v168.
[26]	张泓.导管相关血流感染的急诊临床诊治[J].临床急诊杂志,2019,20(9):672-675.
[27]	Baier C,Linke L,Eder M,et al.Incidence,risk factors and healthcare costs of central line-associated nosocomial bloodstream infections in hematologic and oncologic patients[J].PLoS One,2020,15(1):e0227772.
[28]	Javeri Y,Jagathkar G,Dixit S,et al.Indian Society of Critical Care Medicine Position Statement for Central Venous Catheterization and Management 2020[J].Indian J Crit Care Med,2020,24(Suppl 1):S6-S30.
[29]	Branca JJV,Gulisano M,Nicoletti C.Intestinal epithelial barrier functions in ageing[J].Ageing Res Rev,2019,54:100938.
[30]	da Silva Ferreira AR,Wardill HR,Tissing WJE,et al.Pitfalls and novel experimental approaches to optimize microbial interventions for chemotherapy-induced gastrointestinal mucositis[J].Curr Opin Support Palliat Care,2020,14(2):127-134.
[31]	Bow EJ,Loewen R,Cheang MS,et al.Cytotoxic therapy-induced D-xylose malabsorption andinvasive infection during remission-induction therapy for acute myeloid leukemia in adults[J].J Clin Oncol,1997,15(6):2254-2261.
[32]	Rashidi A,Weisdorf DJ.Microbiota-based approaches to mitigate infectious complications of intensive chemotherapy in patients with acute leukemia[J].Transl Res,2020,220:167-181.
[33]	See I,Iwamoto M,Allen-Bridson K,et al.Mucosal barrier injury laboratory-confirmed bloodstream infection:Results from a field test of a new National Healthcare Safety Network definition[J].Infect Control Hosp Epidemiol,2013,34(8):769-776.
[34]	Hueso T,Ekpe K,Mayeur C,et al.Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia:the role of mucosal strengthening[J].Gut Microbes,2020,12(1):1800897.
[35]	Reed D,Sen J,Lassiter K,et al.Prospective Initiative to Reduce Mucosal Barrier Injuries and Bloodstream Infections in Patients With Hematologic Malignancy Receiving Inpatient Chemotherapy[J].JCO Oncol Pract,2020,16(3):e306-e312.
[36]	Heinz WJ,Buchheidt D,Christopeit M,et al.Diagnosis and empirical treatment of fever of unknown origin(FUO)in adult neutropenic patients:guidelines of the Infectious Diseases Working Party(AGIHO)of the German Society of Hematology and Medical Oncology(DGHO)[J].Ann Hematol,2017,96(11):1775-1792.
[37]	Klastersky J,Paesmans M,Rubenstein EB,et al.The Multinational Association for Supportive Care in Cancer risk index:A multinational scoring system for identifying low-risk febrile neutropenic cancer patients[J].J Clin Oncol,2000,18(16):3038-3051.
[38]	Zheng B,Toarta C,Cheng W,et al.Accuracy of the Multinational Association of Supportive Care in Cancer(MASCC)and Clinical Index of Stable Febrile Neutropenia(CISNE)scores for predicting serious complications in adult patients with febrile neutropenia:A systematic review and meta-analysis[J].Crit Rev Oncol Hematol,2020,149:102922.